<?xml version='1.0' encoding='utf-8'?>
<document id="25034211"><sentence text="Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo." /><sentence text="Drug transporters play important roles in the absorption, distribution, and elimination of drugs and thereby, modulate drug efficacy and toxicity" /><sentence text=" With a growing use of poly pharmacy, concurrent administration of herbal extracts that modulate transporter activities with drugs can cause serious adverse reactions" /><sentence text=" Therefore, prediction and evaluation of drug-drug interaction potential is important in the clinic and in the drug development process" /><sentence text=" DA-9801, comprising a mixed extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, is a new standardized extract currently being evaluated for diabetic peripheral neuropathy in a phase II clinical study" /><sentence text="" /><sentence text="The inhibitory effects of DA-9801 on the transport functions of organic cation transporter (OCT)1, OCT2, organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP)1B1, OATP1B3, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) were investigated in HEK293 or LLC-PK1 cells" /><sentence text=" The effects of DA-9801 on the pharmacokinetics of relevant substrate drugs of these transporters were also examined in vivo in rats" /><sentence text="" /><sentence text="DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48" /><sentence text="1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801" /><sentence text=" To investigate whether this inhibitory effect of DA-9801 on OCT1, OCT2, and OAT3 could change the pharmacokinetics of their substrates in vivo, we measured the pharmacokinetics of cimetidine, a substrate for OCT1, OCT2, and OAT3, and of furosemide, a substrate for OAT1 and OAT3, by co-administration of DA-9801 at a single oral dose of 1,000 mg/kg"><entity charOffset="181-191" id="DDI-PubMed.25034211.s12.e0" text="cimetidine" /><entity charOffset="238-248" id="DDI-PubMed.25034211.s12.e1" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.25034211.s12.e0" e2="DDI-PubMed.25034211.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25034211.s12.e0" e2="DDI-PubMed.25034211.s12.e1" /></sentence><sentence text=" Pre-dose of DA-9801 5 min or 2 h prior to cimetidine administration decreased the Cmax of cimetidine in rats"><entity charOffset="43-53" id="DDI-PubMed.25034211.s13.e0" text="cimetidine" /><entity charOffset="91-101" id="DDI-PubMed.25034211.s13.e1" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.25034211.s13.e0" e2="DDI-PubMed.25034211.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25034211.s13.e0" e2="DDI-PubMed.25034211.s13.e1" /></sentence><sentence text=" However, DA-9801 did not affect the elimination parameters such as half-life, clearance, or amount excreted in the urine, suggesting that it did not inhibit elimination process of cimetidine, which is governed by OCT1, OCT2, and OAT3"><entity charOffset="181-191" id="DDI-PubMed.25034211.s14.e0" text="cimetidine" /></sentence><sentence text=" Moreover, DA-9801 did not affect the pharmacokinetic characteristics of furosemide, as evidenced by its unchanged pharmacokinetic parameters"><entity charOffset="73-83" id="DDI-PubMed.25034211.s15.e0" text="furosemide" /></sentence><sentence text="" /><sentence text="Inhibitory effects of DA-9801 on OCT1, OCT2, and OAT3 observed in vitro may not necessarily translate into in vivo herb-drug interactions in rats even at its maximum effective dose" /><sentence text="" /></document>